What does qarziba — total revenues and income mean?

Represents the total financial inflows generated by a specific product or business segment, including royalties, milestone payments, and licensing fees. This metric serves as a primary indicator of the commercial success and market adoption of the asset within the company's portfolio.

Ligand Pharmaceuticals LGND Qarziba — Total revenues and income

Other product segments

Filspari

$11.32M+114%

Captisol

$8.65M—

Kyprolis

$6.74M—

Evomela

$5.94M-31.5%

Rylaze

$3.81M+3.7%

Ohtuvayre

$3.55M—

Ohtuvayre inventors

$3.05M—

Other

$2.59M—

Teriparatide injection

$2.03M+19.2%

Capvaxive

$1.97M—

Vaxneuvance

$1.61M+25.3%

Contract revenue

$110K—

Similar metrics at other companies

IONSRevenue

$203.33M-10.3%

RYTMLicense revenue — Total revenues

$0+100%

EXELLicense revenues — Total revenues

$56.95M+34.1%

BIIBQALSODY — Total Revenue

$32.5M+110%

PSXRevenues And Other Income

$33B+4.0%

RPRXIncome from financial royalty assets — Total income and other revenues

$594.99M+10.3%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's qarziba — total revenues and income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's qarziba — total revenues and income?: Ligand Pharmaceuticals (LGND) reported qarziba — total revenues and income of $6.3M in Q1 2026.
How has Ligand Pharmaceuticals's qarziba — total revenues and income changed year-over-year?: Ligand Pharmaceuticals's qarziba — total revenues and income increased by 15.7% year-over-year, from $5.44M to $6.3M.
What does qarziba — total revenues and income mean?: Represents the total financial inflows generated by a specific product or business segment, including royalties, milestone payments, and licensing fees. This metric serves as a primary indicator of the commercial success and market adoption of the asset within the company's portfolio.